Skip to main content
Home
FULL MENU Close Menu
Home
Home

Jeff Evans

Jeff Evans has been editor of Rheumatology News/MDedge Rheumatology and the EULAR Congress News since 2013. He started at Frontline Medical Communications in 2001 and was a reporter for 8 years before serving as editor of Clinical Neurology News and World Neurology, and briefly as editor of GI & Hepatology News. He graduated cum laude from Cornell University (New York) with a BA in biological sciences, concentrating in neurobiology and behavior.

News

Inflectra becomes first FDA-approved biosimilar for inflammatory diseases

Author:
Jeff Evans
Publish date: April 5, 2016

  • Read More

News

Cutaneous lupus may raise risk of stroke, TIA

Author:
Jeff Evans
Publish date: March 31, 2016

  • Read More

News

Parkinson’s disease psychosis drug gets favorable review from FDA advisory panel

Author:
Jeff Evans
Publish date: March 29, 2016

  • Read More

News

Parkinson’s disease psychosis drug gets favorable review from FDA advisory panel

Author:
Jeff Evans
Publish date: March 29, 2016
  • Read More

News

Lupus patients’ transition to adult care leaves gaps, delays in care

Author:
Jeff Evans
Publish date: March 25, 2016

Key clinical point: Lupus patients undergoing transition need better education on the importance of prompt follow-up care with adult...

  • Read More

News

Home infusion policies called out in ACR position statement

Author:
Jeff Evans
Publish date: March 22, 2016

  • Read More

News

Antisclerostin osteoporosis drugs might worsen or unmask rheumatoid arthritis

Author:
Jeff Evans
Publish date: March 21, 2016

  • Read More

News

ACR’s 2016-2020 research agenda built through consensus

Author:
Jeff Evans
Publish date: March 18, 2016

  • Read More

News

Registry study adds evidence for use of DMARD combo first in early RA

Author:
Jeff Evans
Publish date: March 10, 2016

Key clinical point: A treat-to-target strategy that uses combination DMARD therapy for early RA provides the quickest time to first remission....

  • Read More

News

Once-daily tofacitinib formulation gets FDA clearance for RA

Author:
Jeff Evans
Publish date: February 25, 2016

  • Read More

News

Anticancer drug bexarotene inhibits build-up of toxic Alzheimer’s protein

Author:
Jeff Evans
Publish date: February 12, 2016

  • Read More

News

Fibromyalgia found in 20% with spondyloarthritis; could affect management decisions

Author:
Jeff Evans
Publish date: February 11, 2016

Key clinical point: Coexistence of fibromyalgia in patients diagnosed with spondyloarthritis might be slightly more frequent than previously...

  • Read More

News

Greater myocardial inflammation found in RA patients after heart attack

Author:
Jeff Evans
Publish date: February 10, 2016

Key clinical point:Post-MI autopsy data support the view that RA patients have greater intramyocardial inflammatory burden than do patients...

  • Read More

News

Greater Myocardial Inflammation Found in RA Patients After Heart Attack

Author:
Jeff Evans
Publish date: February 10, 2016

Key clinical point:Post-MI autopsy data support the view that RA patients have greater intramyocardial inflammatory burden than do patients...

  • Read More

News

Study confirms value of watching JCV serology during natalizumab treatment

Author:
Jeff Evans
Publish date: January 27, 2016

Key clinical point: Keep watch over patients’ anti-JCV seroconversion and JCV index values during treatment with natalizumab to help determine...

  • Read More

Pages

  • « first
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • last »

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close